These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23118302)

  • 1. Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy.
    Chu AY; Guilianini F; Grallert H; Dupuis J; Ballantyne CM; Barratt BJ; Nyberg F; Chasman DI; Ridker PM
    Circ Cardiovasc Genet; 2012 Dec; 5(6):676-85. PubMed ID: 23118302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
    Chasman DI; Giulianini F; MacFadyen J; Barratt BJ; Nyberg F; Ridker PM
    Circ Cardiovasc Genet; 2012 Apr; 5(2):257-64. PubMed ID: 22331829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.
    Ridker PM; MacFadyen JG; Wolfert RL; Koenig W
    Clin Chem; 2012 May; 58(5):877-86. PubMed ID: 22419750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
    Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂.
    Rizos CV; Liberopoulos EN; Tellis CC; Florentin M; Elisaf MS; Tselepis AD
    Metab Syndr Relat Disord; 2011 Jun; 9(3):217-23. PubMed ID: 21352079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.
    Chu AY; Guilianini F; Barratt BJ; Nyberg F; Chasman DI; Ridker PM
    Circ Cardiovasc Genet; 2012 Feb; 5(1):58-65. PubMed ID: 22230323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of lifestyle counseling and combination lipid-modifying therapy on lipoprotein-associated phospholipase A2 mass concentration.
    Reddy KJ; Singh M; Batsell RR; Bangit JR; Miraskar RA; Zaheer MS; Cockerham C; Wegner M
    J Clin Lipidol; 2009 Aug; 3(4):275-80. PubMed ID: 21291824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study.
    Suchindran S; Rivedal D; Guyton JR; Milledge T; Gao X; Benjamin A; Rowell J; Ginsburg GS; McCarthy JJ
    PLoS Genet; 2010 Apr; 6(4):e1000928. PubMed ID: 20442857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
    Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
    Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.
    Reddy KJ; Singh M; Batsell RR; Bangit JR; Miraskar RA; Zaheer MS
    Prev Cardiol; 2010; 13(3):130-4. PubMed ID: 20626668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies.
    Grallert H; Dupuis J; Bis JC; Dehghan A; Barbalic M; Baumert J; Lu C; Smith NL; Uitterlinden AG; Roberts R; Khuseyinova N; Schnabel RB; Rice KM; Rivadeneira F; Hoogeveen RC; Fontes JD; Meisinger C; Keaney JF; Lemaitre R; Aulchenko YS; Vasan RS; Ellis S; Hazen SL; van Duijn CM; Nelson JJ; März W; Schunkert H; McPherson RM; Stirnadel-Farrant HA; Psaty BM; Gieger C; Siscovick D; Hofman A; Illig T; Cushman M; Yamamoto JF; Rotter JI; Larson MG; Stewart AF; Boerwinkle E; Witteman JC; Tracy RP; Koenig W; Benjamin EJ; Ballantyne CM
    Eur Heart J; 2012 Jan; 33(2):238-51. PubMed ID: 22003152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study.
    Furberg CD; Nelson JJ; Solomon C; Cushman M; Jenny NS; Psaty BM
    J Am Geriatr Soc; 2008 May; 56(5):792-9. PubMed ID: 18363676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.
    Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Liamis GL; Kakaidi B; Tselepis AD; Cariolou MA; Elisaf MS
    Arch Med Res; 2007 May; 38(4):403-10. PubMed ID: 17416287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of gender on lipoprotein-associated phospholipase A2 activity and association with known cardiovascularrisk factors].
    Jia ZR; Zhao D; Qi Y; Wang W; Wang M; Sun JY; Qin LP; Liu J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Nov; 41(11):962-7. PubMed ID: 24370228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
    Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
    Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of V279F in the Lp-PLA(2) gene on markers of oxidative stress and inflammation in Koreans.
    Paik JK; Chae JS; Jang Y; Kim JY; Kim OY; Jeong TS; Lee SH; Lee JH
    Clin Chim Acta; 2010 Apr; 411(7-8):486-93. PubMed ID: 20080080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.